IGF-1 DES (1-3): Evidence, Mechanism, Dosing & Legal Status

IGF-1 DES (1-3) is an N-terminally truncated form of insulin-like growth factor-1, missing the first three residues (Gly-Pro-Glu) and thus 67 rather than 70 amino acids (molecular formula C319H501N91O96S7, molar mass ~7,371 g/mol, CAS 112603-35-7).1 It is heavily marketed in physique circles for targeted, localized muscle growth; its proof in humans is nonexistent. This monograph separates the genuine preclinical science from the anecdote.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. IGF-1 DES (1-3) is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is IGF-1 DES (1-3) and how does it work?

Des(1-3)IGF-I is not a wholly synthetic construct. It occurs naturally — isolated from bovine colostrum, human brain and porcine uterus — and is generated in vivo by enzymatic cleavage of circulating IGF-1.25 It is distinct from the fully synthetic Long-R3-IGF-1 (LR3), which adds an N-terminal extension and an Arg3 substitution to pursue a longer half-life by the same binding-protein-evasion strategy.

The truncation preserves the B- and C-domain receptor-binding interface, so des(1-3)IGF-I is a full IGF-1 receptor (IGF-1R) agonist: receptor engagement and downstream signaling closely mirror intact IGF-1, activating PI3K/Akt/mTOR (protein synthesis, anti-apoptotic) and MAPK/ERK (proliferative) cascades.112 Because of structural homology to insulin, IGF-1 ligands including DES also weakly cross-activate the insulin receptor — the basis of the hypoglycemia risk.

The core mechanism is IGFBP escape. In circulation about 99% of IGF-1 is bound by IGF-binding proteins (chiefly IGFBP-3), limiting the free, bioactive fraction. Removing the N-terminal tripeptide, and specifically the Glu3 residue, sharply lowers IGFBP affinity — competitive-binding work shows roughly 25- to 100-fold reduced binding to IGFBP-3 — so far more DES is immediately receptor-available.110 This, not any increase in IGF-1R affinity (which is essentially unchanged), explains the potency gain, which runs from about 2.5-fold in vivo in catabolic rats to about 10-fold in cell-proliferation and dwarf-mouse models.34 The same escape that boosts potency also shortens duration of action: with no binding-protein reservoir, DES is cleared rapidly, with secondary peptide-literature sources citing a plasma half-life on the order of 20-30 minutes — figures from commercial sources, not a primary human PK trial.1819

What is the evidence by indication?

No human randomized controlled trials of des(1-3)IGF-I exist for any indication. Every efficacy finding below is animal or in-vitro, graded C, except the bodybuilding use, which is anecdotal and graded D. For context, the broader IGF-1 receptor literature is itself almost entirely preclinical; readers can confirm the absence of registered human DES efficacy trials by searching ClinicalTrials.gov, which returns no qualifying efficacy study.

The strongest dataset is rodent anti-catabolism. In dexamethasone-treated catabolic rats, des(1-3)IGF-I reversed steroid-induced weight loss, cut muscle protein breakdown (3-methylhistidine excretion fell from 83.5 to 65.1 µmol/kg/7 d), improved nitrogen retention, and was about 2.5-fold more potent than intact IGF-1.3 In diabetic rats, IGF-I and des(1-3)IGF-I increased weight gain, nitrogen retention and muscle protein synthesis.8 These are animal models of catabolic illness, not athletic recovery. DES also shows pronounced gut-trophic effects: enhanced growth after gut resection and marked gut growth in dexamethasone-treated rats, with gut weight rising up to ~45% in the Tomas study — historically suggestive for catabolic or inflammatory-bowel indications, but never developed to approval.79

What doses appear in the literature?

Reported strictly as information, not a protocol, and not validated for human use. In definitive preclinical work, DES was given by continuous subcutaneous infusion via implanted osmotic minipump in rats, in dose-ranging designs comparing IGF-I, des(1-3)IGF-I and LR3; DES achieved equivalent anabolic effect at lower doses than IGF-I, consistent with its ~2.5-fold in-vivo potency, and continuous infusion was used precisely because of the short half-life.3 Anecdotal human bodybuilding accounts from secondary commercial sources describe localized intramuscular injection of roughly 20-150 µg into a trained muscle, often peri-workout, exploiting the brief half-life for a local pulse — but no clinical trial, dose-finding or safety study supports these figures.1819 As a peptide, DES is not orally bioavailable; preclinical administration was parenteral and anecdotal human use is by injection.

How safe is IGF-1 DES (1-3)?

There is no controlled human safety dataset; the profile is inferred from IGF-1 pharmacology, animal data and theoretical risk. Hypoglycemia is the most commonly cited acute risk, driven by IGF-1R activation plus weak insulin-receptor cross-reactivity, and DES's higher free-fraction potency could amplify it.20 The same site-targeting that anecdotal users seek raises a risk of disproportionate local growth, tissue distortion or lipohypertrophy at injection sites — a direct consequence of potent local IGF-1R agonism. The dominant long-term concern is mechanistic: IGF-1 signaling is anti-apoptotic and proliferative, and elevated IGF-1-axis activity is epidemiologically associated with certain cancers, so a potent IGFBP-evading agonist carries a theoretical risk of promoting growth of existing or occult neoplasia, alongside pro-angiogenic (proliferative-retinopathy) and organomegaly concerns.1620 Theoretically contraindicated or cautioned populations include anyone with active or prior cancer, pregnancy and lactation, diabetes or hypoglycemia risk, proliferative retinopathy, and children or adolescents with open growth plates. In practice an additional risk is product quality: research-chemical supply is unregulated, so purity, dose accuracy, endotoxin and sterility are not assured.17

What is the FDA and WADA status in 2026?

Des(1-3)IGF-I has no FDA approval for any human indication. The only FDA-approved IGF-1 product is mecasermin (Increlex), full-length recombinant human IGF-1 for severe primary IGF-1 deficiency, and that approval does not extend to truncated analogues like DES.17 IGF-1 analogues are not legally compoundable for human administration: following October 2023 FDA warning letters and 2024 clarifications, numerous research peptides were treated as inappropriate for compounding (Category-2-type), so clinics dispensing them for human use operate outside federal law.16 DES is sold only as a laboratory research reagent — the "research use only" label is a compliance restriction for bona fide in-vitro use, not a legal pathway for personal or clinical administration. It is not a DEA-scheduled substance, but that does not make human use lawful.17

For athletes the picture is unambiguous. Under the WADA 2026 Prohibited List, Section S2.3 (Growth Factors and Growth Factor Modulators), "insulin-like growth factor-1 (IGF-1, mecasermin) and its analogues" are prohibited at all times — in and out of competition — language that explicitly captures des(1-3)IGF-I and related variants such as LR3 and MGF.1415 Detection can yield suspension, results forfeiture and bans. Any WADA-tested athlete should treat IGF-1 DES as banned.

Bottom line. IGF-1 DES (1-3) is a scientifically interesting preclinical IGF-1 tool with no established human therapeutic role. In rodent and cell models it is a genuinely more potent receptor agonist because it escapes IGFBP sequestration, with measurable anti-catabolic, protein-sparing and gut-trophic effects (grade C). The headline use — localized post-workout injection for targeted human muscle growth — rests on anecdote and mechanism only (grade D), with no controlled human data and unknown human dose, efficacy and long-term safety. It is not FDA-approved, not legally compoundable, and WADA-banned at all times; the evidence does not support human use and the risk profile argues against it outside bona fide laboratory research.